What Sufentanil Renaudin Treats: Main Uses and Benefits

Sufentanil Renaudin is utilized in various medically supervised settings for managing severe pain. It is an analgesic that is used to help control discomfort and provide relief during intensive medical procedures.

The medicine’s approved indications include its use as an analgesic adjunct to general anesthesia for intubated and ventilated patients, as a primary anesthetic agent for induction and maintenance of anesthesia during major surgical procedures (such as cardiovascular or certain neurosurgical procedures), and as an analgesic via epidural administration during labor and vaginal delivery.

The core benefit is to help manage pain and provide relief from profound discomfort in situations where alternative treatments are inadequate. As an analgesic, it assists in keeping the patient comfortable during the course of medical care.

“The primary clinical benefit is the relief of severe pain, to assist in comfort during medical care.”

---

Quick Fact: Relief for Severe Pain

Eligibility Status

Sufentanil Renaudin is officially allowed for Adults for both intravenous and epidural use. Pediatric eligibility is established for certain children, typically those younger than 12 years of age undergoing major surgery. However, its use is not established for children younger than 2 years of age. Geriatric patients may be eligible but require cautious dose selection due to the greater frequency of decreased organ function.

---

Absolute Contraindications

The medicine is strictly contraindicated for patients with a known hypersensitivity to Sufentanil, other opioid agonists, or any component of the formulation. It is also contraindicated for individuals with known or suspected mechanical gastrointestinal obstruction, including paralytic ileus.

---

Restrictions and Conditional Use

Conditional use and close monitoring are required for certain populations. This includes patients with severe renal impairment or hepatic impairment, Chronic Pulmonary Disease, and conditions associated with increased intracranial pressure. Patients with seizure disorders also require monitoring for worsened seizure control.

---

Pregnancy and Labor Restrictions

Intravenous use is not recommended immediately before or during labor or before clamping the umbilical cord. Prolonged use during pregnancy may result in Neonatal Opioid Withdrawal Syndrome. Since Sufentanil is excreted in human milk, infants exposed through breastfeeding must be monitored for signs of excess sedation.

Interactions with other medicines and products

The concomitant use of Sufentanil Renaudin with other agents that cause central nervous system (CNS) depression presents a significant risk. These include benzodiazepines, other opioids, general anesthetics, sedatives, hypnotics, and alcohol. The combination can lead to enhanced effects, such as profound sedation, respiratory depression, coma, and potentially death. Concomitant prescribing is reserved only for patients when alternative treatments are inadequate, and dosages must be strictly limited, with patients closely monitored for signs of respiratory compromise.

Sufentanil is metabolized by the enzyme Cytochrome P450 3A4 (CYP3A4). The use of CYP3A4 inhibitors (such as certain antifungal agents or antiretrovirals like ketoconazole or ritonavir) can reduce the clearance of sufentanil, leading to elevated plasma concentrations. This pharmacokinetic interaction increases the risk of prolonged or delayed respiratory depression and overdose. Conversely, co-administration with CYP3A4 inducers (which increase enzyme activity) or their discontinuation requires monitoring, as it can affect sufentanil levels.

Concomitant use with serotonergic drugs (e.g., SSRIs, SNRIs) may lead to an increased risk of Serotonin Syndrome, a potentially life-threatening condition. Additionally, the use of mixed agonist/antagonist or partial agonist opioid analgesics (like buprenorphine or nalbuphine) should be avoided as they may precipitate opioid withdrawal symptoms or reduce the analgesic effect of sufentanil.

Sufentanil Renaudin is a synthetic opioid that achieves its action by acting as a full agonist at the mu-opioid receptor (MOR) within the central nervous system. Upon binding, the compound causes a conformational change in the receptor, which initiates coupling to an inhibitory G-protein. The activated G-protein, specifically the mathrmGmathrmi subunit, regulates two primary intracellular pathways.

First, mathrmGmathrmi coupling inhibits the enzyme adenylate cyclase, resulting in a reduction of intracellular cyclic AMP (cAMP) levels. This cascade modulates the release of key excitatory neurotransmitters from presynaptic terminals. Second, this mathrmGmathrmi-mediated effect also activates inwardly rectifying potassium channels (K ir channels). The resulting potassium efflux causes hyperpolarization of the neuronal membrane, leading to reduced neuronal excitability.

How to use Sufentanil Renaudin — Official Administration Guidelines

Sufentanil is administered exclusively in a certified medically supervised healthcare setting, such as a hospital or surgical center, by trained healthcare professionals. The medicine is utilized on an as-needed (PRN) basis, with administration limited to the duration of the acute medical procedure.

---

Administration Scope

Property	Official Administration Instruction
Route of administration	Approved for Intravenous (IV) injection or infusion, Epidural injection, and Sublingual (SL) use.
Dosing schedule	IV Analgesic Adjunct: Initial dose 1 to 2 mu g/kg. IV Primary Anesthetic: Total dose 8 to 30 mu g/kg. SL: 30 mu g per dose.
Timing in relation to meals (if applicable)	For the sublingual tablet, patients should avoid eating or drinking for 10 minutes after administration.
Preparation requirements (if applicable)	Parenteral solution should be visually inspected, and IV bolus doses must be administered slowly over three to five minutes.
Age-group administration rules	Older Adults (>65): Lower initial doses are generally recommended. Children (2–12 years): A reduced initial dose as low as 2 to 3 mu g/kg is recommended.
Special procedural conditions	Sublingual tablets must not be chewed or swallowed and are for single use only. SL use is restricted to a maximum duration of 72 hours.

---

Resulting Procedural Structure

The official instructions establish a highly controlled protocol that mandates administration via IV, epidural, or sublingual routes only within certified medical settings. The dosing is strictly structured by the procedural role (e.g., anesthetic adjunct versus primary anesthetic) and is not intended for chronic, long-term use. This framework defines the precise technique and necessary preparation required for proper administration by trained healthcare professionals.

Sufentanil Renaudin: Overview of Studies

This summary outlines the available research evidence for Sufentanil Renaudin, describing the types of studies conducted and what their findings indicate, without offering any clinical advice or making claims about guaranteed outcomes. The goal of this overview is to help contextualize what is known—and what remains uncertain—about the drug's use in medically supervised settings.

Evidence for Use in General Anesthesia and Major Surgery

Intravenous Sufentanil was studied for use in general anesthesia, both as a primary agent in major procedures and as a supplementary analgesic in research contexts involving fluctuating symptoms during surgery. Research has examined the effects of Sufentanil through extensive Randomized Controlled Trials (RCTs) and systematic reviews. Key outcomes measured included the time required for a patient to wake up and be ready for extubation, the monitoring of physiological strain (hemodynamic parameters) during surgery, and the use of rescue analgesia in the postoperative period.

Research highlighted changes measured during the study period in the time to recovery when Sufentanil was compared to Remifentanil; some analyses reported a longer time to tracheal extubation, while others described data show patterns related to reduced use of rescue analgesia in the postoperative setting.

Evidence for Use in Epidural Analgesia During Labor

Sufentanil was evaluated in research exploring how symptoms change over time (regional pain) for labor and vaginal delivery. RCTs and meta-analyses have explored its application in parturients (women in labor). The research examined outcomes related to patient-reported outcomes describing perceived discomfort during the first stage of labor, and also monitored neonatal outcomes, including Apgar scores.

Research describes that when used as an adjunct in the epidural space, Sufentanil was associated with outcomes related to physical discomfort (pain scores) and research highlights changes measured during the study period.

Long-term Follow-up and Duration of Data

The available evidence is focused on short-term symptom patterns that align with the acute nature of its use during surgery and labor. Long-term effects are not fully established and there is limited information for long-term outcomes beyond immediate recovery. Research is ongoing to enhance the understanding of the long-term implications of opioid selection in the anesthetic setting.

Key Studies & References

1. Comparison of the recovery profile of sufentanil and remifentanil in total intravenous anesthesia: a systematic review and meta-analysis of randomized controlled trials

Common questions about Sufentanil Renaudin (FAQ)

---

Q: How quickly does Sufentanil Renaudin start to work and how long does the effect last?

Official product information describes Sufentanil as an opioid with a rapid onset of action. Regulatory documents describe a rapid onset of action, which indicates the effects start quickly after administration. The duration of the effect is relatively short after a single intravenous dose, though the time the medicine remains in the body, known as the terminal elimination half-life, can vary widely depending on the type of administration and whether the dose is single or repeated.

---

Q: Are there any foods or drinks I should avoid while on Sufentanil Renaudin?

Regulatory documents state that if the sublingual tablet form is used, official guidelines state that eating or drinking should be avoided for 10 minutes after the tablet is administered to allow for proper absorption. This restriction is specific to the sublingual form, and official guidance on the intravenous or epidural forms does not mention specific food interactions.

---

Q: Is Sufentanil Renaudin contraindicated for patients with a history of drug dependence?

Sufentanil is classified as an opioid, which inherently carries risks of addiction, abuse, and misuse. Prescribing information indicates that a risk assessment, which may include evaluating a patient's history related to dependence, is generally conducted by a healthcare provider prior to administration. The drug is generally reserved only for patients when alternative treatments are considered inadequate.

---

Q: Does Sufentanil Renaudin affect my ability to drive or operate machinery?

According to the official product information, Sufentanil has a major influence on a person’s ability to drive and use machines. Due to the potential effects of the medication, warnings caution against driving or operating machinery for a specific period following treatment, as determined by a healthcare provider.

---

Q: Can Sufentanil Renaudin cause mental or mood changes, such as confusion or anxiety?

Official product information indicates that mental and mood changes are reported as possible undesirable effects. These changes can include experiencing a confused state, feeling dizziness or anxiety, or feeling somnolent (drowsy). Other reported mood effects include a feeling of euphoria.

---

Q: Can Sufentanil Renaudin be used for prolonged sedation in the Intensive Care Unit (ICU)?

Official documents note that when Sufentanil is administered over a long period, such as for prolonged sedation in an intensive care setting, there is a risk of developing physical dependence. This extended use carries the potential for developing physical dependence, which may be associated with tolerance to the drug’s effects and the risk of withdrawal symptoms upon discontinuation.

---

Q: Does Sufentanil Renaudin interact with my blood pressure medications?

Official information indicates that Sufentanil may cause severe hypotension (low blood pressure) as an adverse reaction. Concomitant use with other Central Nervous System (CNS) depressants can also increase the risk of low blood pressure. For patients with existing conditions or who are taking medications that affect blood pressure, close monitoring is generally part of the prescribed protocol.

---

Q: Why is Sufentanil Renaudin sometimes given in a very low dose?

Sufentanil is administered in a range of dosages depending on the medical need. Official labeling shows that the lowest doses are generally used as an analgesic adjunct, meaning it is given to supplement the main general anesthetic. This contrasts with higher doses that may be required when the medication is used as a primary anesthetic agent.

---

Q: If I only take Sufentanil for a short time, will suddenly stopping it cause withdrawal symptoms?

Physical dependence is a documented risk associated with Sufentanil, even with appropriate therapeutic use. While short-term use for acute pain management carries a risk, patients receiving Sufentanil are typically monitored for signs of physical dependence and potential withdrawal when the medication is discontinued.

Sufentanil Renaudin (Sufentanil Citrate Injection) is a Schedule II controlled substance that requires strict adherence to official storage and disposal protocols, as defined by regulatory labeling.

Storage Conditions

Requirement	Official Statement
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F)
Protection	Protect from light and retain in carton until time of use
Safety	Keep all drugs out of the reach of children and pets

Disposal Instructions

Disposal must prevent accidental exposure, which can be fatal. The unused or expired medicine should be returned via a drug take-back program or mail-back envelope.

If these options are not readily available, the FDA recommends that this powerful narcotic be immediately flushed down the toilet to eliminate the risk of accidental ingestion in the home.